摘要
目的探讨阿戈美拉汀治疗老年卒中后抑郁（post—stroke depression，PSD）的有效性和安全性。方法80例老年PSD患者随机分为阿戈美拉汀组和舍曲林组，在治疗前和治疗后第1、2、4、6周分别应用汉密尔顿抑郁量表（Hamilton DepressionScale，HAMD）、美国国立卫生研究院卒中量表（National Institutes of Health Stroke Scale，NIHSS）和Barthel指数进行评价。结果阿戈美拉汀组（n=38）和舍曲林组（n：42）HAMD、NIHSS和Barthel指数评分均随着时间的推移显著改善（P均〈0．001）。阿戈美拉汀组与舍曲林组HAMD和NIHSS评分在治疗后不同时间点组问无显著性差异，而Barthel指数评分从治疗后第4周开始出现显著性差异（P均〈0．05）。结论阿戈美拉汀治疗PSD的疗效与舍曲林相当，且其改善日常生活能力的效果优于舍曲林，两者安全性均良好。
Objective To investigate the effectiveness and safety of agomelatine for the treatment of elderly patients with post-stroke depression.Methods A total 80 elderly patients with post-stroke depression were randomly divided into either an agomelatine group or a sertraline group. The Hamilton Depression Scale （HAMD）, National Institutes of Health Stroke Scale （NIHSS） and I^thel Index were used to evaluate the patients before and after 1,2, 4, and 6 weeks, respectively.Results HAMD, NIHSS, and Barthel index scores were improved significantly after treatment in the agomehtine group （n = 38） and the sertraline group （n = 42）. There were significant improvement in the scores of HAMD, NIHSS and Barthel Index with time in both groups （all P 〈0. 001）. There were no significant difference in the scores of HAMD and NIHSS at different time points after treatment between the agomelatine group and the sertraline group, and the Barthel Index scores began to have significance difference from the fourth week after treatment （all P〈 0. 05）. Conclusions The efficacy of agomelatine for the treatment of PSD is almost the same as sertraline, and the effect of improving activities of daily riving is better than sertraline. The safety of both agomelatine and sertraline is good.
出处
《国际脑血管病杂志》
北大核心
2014年第12期907-910,共4页
International Journal of Cerebrovascular Diseases
基金
佛山市科技局基金（201308291）
关键词
卒中
抑郁障碍
舍曲林
治疗结果
阿戈美拉汀
Stroke
Depressive Disorder
Sertraline
Treatment Outcome
Agomelatine
